NBIX
NMS 股策精挑入选日 2026-07-08 · 入选 50 天AI选股记录
总览这个股票来自自动 AI 选股池。以后只要 CLI 写入新的 ticker，这里会自动生成个股页面，不需要手工补页面。
基本信息
成交结构
基于近 60 日量价数据观察资金强弱。
交易信号历史
按时间回看该股票被模型捕捉到的买点信号。
| 信号日期 | 模型来源 | 评分/强度 | 信号价格 | 止损价 | 止盈价 | 当前表现 | 操作结论 |
|---|---|---|---|---|---|---|---|
| 2026-07-17 | 综合评分 | 80 | $171.55 | $159.78 | $195.10 | -9.5% | 可买入 |
| 2026-07-17 | 动量强势 | +23.0% | $171.55 | $164.69 | $185.27 | -9.5% | 可买入 |
| 2026-07-16 | 综合评分 | 80 | $172.05 | $159.04 | $198.07 | -9.8% | 可买入 |
| 2026-07-16 | 动量强势 | +26.4% | $172.05 | $165.17 | $185.81 | -9.8% | 可买入 |
| 2026-07-02 | 综合评分 | 78 | $167.77 | $150.99 | $201.32 | -7.5% | 可买入 |
| 2026-07-01 | 综合评分 | 78 | $168.53 | $151.68 | $202.24 | -7.9% | 可买入 |
| 2026-07-01 | 股策精挑 | 64 | $168.53 | $155.05 | $195.50 | -7.9% | 可买入 |
| 2026-06-30 | 综合评分 | 78 | $170.00 | $153.00 | $204.00 | -8.7% | 可买入 |
| 2026-06-29 | 综合评分 | 78 | $168.52 | $151.67 | $202.22 | -7.9% | 可买入 |
| 2026-06-29 | 股策精挑 | 74 | $168.52 | $155.04 | $195.48 | -7.9% | 可买入 |
公司简介
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
最新资讯
